Bladder Cancer Global Clinical Trial Landscape (2024)

Bladder cancer is the ninth most common cancer in the world and thirteenth in mortality. The market for treating this disease is diverse, and companies have developed various therapeutic modalities to target different aspects of bladder cancer. Evolving treatments and strategies for this disease show significant advancements in areas such as immunotherapies, targeted therapies, combination therapies, and gene therapies. This report provides a detailed overview of the clinical trial landscape for this cancer and the burden it has placed on locations across the globe. It explores the prevalence of bladder cancer by region, the current standard of care, trial density and patient recruitment, ongoing phase III trials, the drug development landscape, and more.